The latest price target for Haemonetics (NYSE:HAE) was reported by JP Morgan on December 6, 2024. The analyst firm set a price target for $116.00 expecting HAE to rise to within 12 months (a possible 54.17% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Haemonetics (NYSE:HAE) was provided by JP Morgan, and Haemonetics initiated their overweight rating.

The last upgrade for Haemonetics Corp happened on November 8, 2024 when Raymond James raised their price target to $120. Raymond James previously had an outperform for Haemonetics Corp.

The last downgrade for Haemonetics Corp happened on January 27, 2022 when Needham changed their price target from N/A to N/A for Haemonetics Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a initiated with a price target of $0.00 to $116.00. The current price Haemonetics (HAE) is trading at is $75.24, which is within the analyst’s predicted range.